Johnson & Johnson Shuts Down Brisbane R&D Center Amid Strategic Shift

Johnson & Johnson (J&J) is closing its nearly 200,000 square-foot research and development (R&D) outpost in Brisbane, California, less than 18 months after its grand opening. This decision was confirmed by a J&J spokesperson, emphasizing the company’s ongoing commitment to California through its pharma and medtech units and establishing an Innovation Center. The closure of the San Francisco Bay Campus (SFBC), announced to staff recently, comes despite the initial enthusiasm and significant investment in expanding J&J’s R&D capabilities in the Bay Area, focusing on gene and RNA-based therapies and retinal and infectious diseases research. The move reflects a broader strategic realignment within J&J, marked by a reduction in focus on specific pharma priorities, including infectious disease and vaccine research. The company continues to emphasize its dedication to innovation and patient impact amidst adjustments in its operational focus and a record R&D expenditure in 2023.

To read more, click here.

[Source: Fierce Biotech, February 25th, 2024]